Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer

NCT01583322 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

188

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: vargatef
DRUG: placebo

Sponsor

ARCAGY/ GINECO GROUP